Home  |  About us  |  Editorial board  |  Ahead of print  | Current issue  |  Archives  |  Submit article  |  Instructions |  Search  |   Subscribe  |  Advertise  |  Contacts  |  Login 
  Users Online: 238Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
This article has been cited by
1Expanding Patient Access to Investigational New Drugs
Gail A. Van Norman
JACC: Basic to Translational Science.2018;3(3)403
[DOI]
2Identification, Prioritization, and Treatment of Mutations Identified by Next-Generation Sequencing
Aaron S. Mansfield,Ben Ho Park,Michael P. Mullane
American Society of Clinical Oncology Educational Book.2018;3(38)873
[DOI]
3Alternative access schemes for pharmaceuticals in Europe: Towards an emerging typology
Olga Löblová,Marcell Csanádi,Piotr Ozieranski,Zoltán Kaló,Lawrence King,Martin McKee
Health Policy.2019;123(7)630
[DOI]
4Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma
Ajai Chari,Sagar Lonial,Tomer M. Mark,Amrita Y. Krishnan,Keith E. Stockerl-Goldstein,Saad Z. Usmani,Anil Londhe,Delores Etheredge,Sarah Fleming,Baolian Liu,Jon Ukropec,Thomas S. Lin,Sundar Jagannath,Ajay K. Nooka
Cancer.2018;124(22)4342
[DOI]
5Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma
Louise E. Curley,Maree Jensen,Zaheer-Ud-Din Babar,Sanya Ram
Cancer.2018;124(22)183
[DOI]
6Patterns of alternative access: Unpacking the Slovak extraordinary drug reimbursement regime 2012-2016
Olga Löblová,Marcell Csanádi,Piotr Ozieranski,Zoltán Kaló,Lawrence King,Martin McKee
Health Policy.2019;124(22)183
[DOI]
7To the Editor, A multicenter, open-label, early access treatment protocol for ibrutinib in patients with relapsed or refractory mantle cell lymphoma
Peter Martin,Andre Goy,Radhakrishnan Ramchandren,Lucille Ferrante,Anil Londhe,Tracy McGowan,Nancy L Bartlett
Journal of Oncology Pharmacy Practice.2019;25(4)1027
[DOI]
8Physician perspectives on compassionate use in pediatric oncology
Scott Moerdler,Lindy Zhang,Elena Gerasimov,Chong Zhu,Tamar Wolinsky,Michael Roth,Nancy Goodman,Daniel A. Weiser
Pediatric Blood & Cancer.2019;66(3)e27545
[DOI]
9An overview of Compassionate Use Programs in the European Union member states
Gayathri Balasubramanian,Suman Morampudi,Pankdeep Chhabra,Arun Gowda,Behsad Zomorodi
Intractable & Rare Diseases Research.2016;5(4)244
[DOI]
10A retrospective study of trifluridine/tipiracil in pretreated metastatic colorectal cancer patients in clinical practice
Beatrice Borelli,Gemma Zucchelli,Daniele Rossini,Chiara Cremolini,Carlotta Antoniotti,Roberto Moretto,Federica Marmorino,Camilla Colombo,Francesca Vannini,Laura Delliponti,Mario Spione,Elena Ongaro,Gianluca Masi,Isa Maura Brunetti,Elisabetta Pfanner,Lisa Salvatore,Alfredo Falcone
Colorectal Cancer.2018;7(1)CRC01
[DOI]
  Feedback 
  Subscribe 

Subscribe this journal
Submit articles
Most popular articles
Joiu us as a reviewer
Email alerts
Recommend this journal